116 Pathologic Predictors of Response to Neoadjuvant Anti-HER2 Therapy in ER+/HER2+ Breast Carcinomas: Time for HER2-High and HER2-Medium Categories?
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Publication details
- Journal / source
- Laboratory Investigation
- Volume
- 106
- Issue
- 3
- Pages
- 104395–104395
- Publication date
- 1 March 2026
- Language
- EN